News

COMPANY NEWS

12 Jun 2026 · 1 min read

REPLAY | FebriDx US Launch Update

Lumos CEO Doug Ward, Lumos Chief Commercial Officer Paul Kase, Lumos Director of U.S. Sales

Read article

COMPANY NEWS

03 Jun 2026 · 2 min read

100+ Locations and Growing: A Milestone for FebriDx® Adoption

FebriDx® has surpassed 100 healthcare locations across 18 states in the United States

Read article

COMPANY NEWS

14 May 2026 · 1 min read

Lumos Achieves 250 Patient Milestone in FebriDx® Paediatric Study

Lumos has achieved enrolment of 250 patients in its BARDA-funded FebriDx® paediatric clinical study, triggering a US$670,000 milestone payment...

Read article

COMPANY NEWS

01 May 2026 · 1 min read

FebriDx® Rollout Gains Momentum with 43 New WellStreet Locations

Following the success of their initial program and supported by the recent granting of CLIA waiver for FebriDx®, WellStreet has now begun testing at 43 additional sites...

Read article

COMPANY NEWS

21 Apr 2026 · 1 min read

REPLAY | Lumos Diagnostics Q3 FY26 Investor Briefing

Lumos Diagnostics recently hosted an investor webinar covering its Q3 FY26 financial results and operational progress.

Read article

COMPANY NEWS

09 Apr 2026 · 1 min read

Lumos secures new contract manufacturing agreement & first purchase order with Micro-Pak®

Lumos has announced that it has secured a new three-year contract manufacturing agreement with Micro-Pak®

Read article

COMPANY NEWS

01 Apr 2026 · 1 min read

Lumos receives largest FebriDx® order to-date from PHASE Scientific

Lumos has announced that it has now received its largest purchase order to-date for FebriDx®...

Read article

COMPANY NEWS

27 Mar 2026 · 1 min read

FDA CLIA Waiver for FebriDx unlocks US$1B+ U.S. opportunity

Lumos Diagnostics has today announced that U.S. FDA has granted 510(k) clearance with CLIA waiver for FebriDx®, enabling broader

Read article

COMPANY NEWS

09 Mar 2026 · 1 min read

REPLAY | Lumos Diagnostics 1H FY26 Investor Briefing

Lumos Diagnostics recently hosted an investor webinar covering its 1H FY26 financial results and operational progress.

Read article

COMPANY NEWS

23 Feb 2026 · 1 min read

Lumos Complete 1st Enrollment Milestone for Paediatric Study

Lumos has announced the completion of the first enrollment milestone in the ongoing BARDA-funded paediatric clinical study

Read article

COMPANY NEWS

24 Dec 2025 · 1 min read

Texas A&M University Health Services Adopts FebriDx® in Student Medical Centers

Lumos Diagnostics (ASX: LDX) is pleased to share that Texas A&M University Health Services has commenced the routine use of FebriDx®

Read article

COMPANY NEWS

22 Oct 2025 · 1 min read

Lumos commences FebriDx® CLIA waived pediatric study

Lumos has commenced its FebriDx® CLIA-waiver pediatric study in the United States, with the first patient successfully enrolled.

Read article